Earnings Feed
Start Free
Home/Filings/4/0001209191-14-050675
4//SEC Filing

IDENIX PHARMACEUTICALS INC 4

Accession 0001209191-14-050675

CIK 0001093649operating
View on SEC.govCompany Profile

Filed

Aug 4, 8:00 PM ET

Accepted

Aug 5, 5:38 PM ET

Size

28.1 KB

Accession

0001209191-14-050675

Insider Transaction Report

Form 4
Period: 2014-08-05
IDENIX PHARMACEUTICALS INCIDIX
Fanning Paul
SVP, Human Resources
Transactions
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2014-08-05−60,000→ 0 total
    Exercise: $12.08Exp: 2022-02-28→ Common Stock (60,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2014-08-05−80,000→ 0 total
    Exercise: $7.01Exp: 2024-02-09→ Common Stock (80,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2014-08-05−35,000→ 0 total
    Exercise: $2.96Exp: 2020-02-09→ Common Stock (35,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2014-08-05−40,000→ 0 total
    Exercise: $3.17Exp: 2021-02-20→ Common Stock (40,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2014-08-05−60,000→ 0 total
    Exercise: $4.65Exp: 2023-02-19→ Common Stock (60,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2014-08-05−15,000→ 0 total
    Exercise: $19.14Exp: 2015-02-27→ Common Stock (15,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2014-08-05−15,000→ 0 total
    Exercise: $21.11Exp: 2016-03-06→ Common Stock (15,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2014-08-05−40,000→ 0 total
    Exercise: $5.18Exp: 2018-02-21→ Common Stock (40,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2014-08-05−15,000→ 0 total
    Exercise: $8.12Exp: 2017-03-05→ Common Stock (15,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2014-08-05−30,000→ 0 total
    Exercise: $5.46Exp: 2019-02-12→ Common Stock (30,000 underlying)
Footnotes (10)
  • [F1]These options, which vested in 48 equal monthly installments beginning on March 31, 2005, were cancelled pursuant to the Agreement and Plan of Merger between the Issuer and Merck & Co. Inc. (the "Merger Agreement") in exchange for a cash payment of $5.36 per share, representing the difference between the exercise price of the options and $24.50 per share.
  • [F10]These options, which vested in 48 equal monthly installments beginning on February 28, 2014, were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $17.49 per share, representing the difference between the exercise price of the options and $24.50 per share.
  • [F2]These options, which vested in 48 equal monthly installments beginning on March 31, 2006, were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $3.39 per share, representing the difference between the exercise price of the options and $24.50 per share.
  • [F3]These options, which vested in 48 equal monthly installments beginning on March 31, 2007, were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $16.38 per share, representing the difference between the exercise price of the options and $24.50 per share.
  • [F4]These options, which vested in 48 equal monthly installments beginning on February 29, 2008, were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $19.32 per share, representing the difference between the exercise price of the options and $24.50 per share.
  • [F5]These options, which vested in 48 equal monthly installments beginning on February 28, 2009, were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $19.04 per share, representing the difference between the exercise price of the options and $24.50 per share.
  • [F6]These options, which vested in 48 equal monthly installments beginning on February 28, 2010, were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $21.54 per share, representing the difference between the exercise price of the options and $24.50 per share.
  • [F7]These options, which vested in 48 equal monthly installments beginning on February 28, 2011, were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $21.33 per share, representing the difference between the exercise price of the options and $24.50 per share.
  • [F8]These options, which vested in 48 equal monthly installments beginning on February 29, 2012, were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $12.42 per share, representing the difference between the exercise price of the options and $24.50 per share.
  • [F9]These options, which vested in 48 equal monthly installments beginning on February 28, 2013, were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $19.85 per share, representing the difference between the exercise price of the options and $24.50 per share.

Documents

1 file

Issuer

IDENIX PHARMACEUTICALS INC

CIK 0001093649

→
Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001093649

Filing Metadata

Form type
4
Filed
Aug 4, 8:00 PM ET
Accepted
Aug 5, 5:38 PM ET
Size
28.1 KB
View on SEC.gov